Skip to main content

Table 1 Baseline characteristics

From: Vision loss in patients with giant cell arteritis treated with tocilizumab

  All
n (%) or median (IQ range)
Total N N = 186
Female 116 (62%)
Age at diagnosis 71.0 (63.0; 77.0)
Weight [kg] 70.0 (59.0; 83.4)
BMI [kg/m2] 24.9 (22.0; 28.4)
CRP (mg/L) 50.0 (20.0; 99.0)
ESR (mm/h) 70.0 (40.0; 86.3)
ACR Criteria 1990 109 (59%)
Cranial symptoms (including visual symptoms) 124 (67%)
Visual symptoms 70 (38%)
Vision loss 21 (11%)
Headache 93 (50%)
Jaw claudication 48 (26%)
Scalp tenderness 42 (23%)
Claudication of tongue 2 (1%)
Fever ≥ 38 °C 35 (19%)
Weight loss > 2 kg within 4 weeks 50 (27%)
Night sweat 33 (18%)
Polymyalgia rheumatica 90 (48%)
Biopsy of the temporal artery performed/positive* 135 (73%)/73 (54%)
MR angiography of aorta performed/positive* 170 (91%)/123 (72%)
MR angiography of extracranial arties performed/positive* 132 (71%)/63 (48%)
PET imaging performed/positive* 20 (11%)/12 (60%)
Duplex ultrasound of extracranial arteries performed/positive* 43 (23%)/18 (42%)
  1. *% positive refers to number performed